Renal differentiation of amniotic fluid stem cells

Childrens Hospital Los Angeles, Saban Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA.
Cell Proliferation (Impact Factor: 3.28). 01/2008; 40(6):936-48. DOI: 10.1111/j.1365-2184.2007.00478.x
Source: PubMed

ABSTRACT The role of stem cells in regenerative medicine is evolving rapidly. Here, we describe the application, for kidney regeneration, of a novel non-genetically modified stem cell, derived from human amniotic fluid. We show that these pluripotent cells can develop and differentiate into de novo kidney structures during organogenesis in vitro.
Human amniotic fluid-derived stem cells (hAFSCs) were isolated from human male amniotic fluid obtained between 12 and 18 weeks gestation. Green fluorescent protein and Lac-Z-transfected hAFSCs were microinjected into murine embryonic kidneys (12.5-18 days gestation) and were maintained in a special co-culture system in vitro for 10 days. Techniques of live microscopy, histology, chromogenic in situ hybridization and reverse transcriptase polymerase chain reaction were used to characterize the hAFSCs during their integration and differentiation in concert with the growing organ.
Green fluorescent protein and Lac-Z-transfected hAFSCs demonstrated long-term viability in organ culture. Histological analysis of injected kidneys revealed that hAFSCs were capable of contributing to the development of primordial kidney structures including renal vesicle, C- and S-shaped bodies. Reverse transcriptase polymerase chain reaction confirmed expression of early kidney markers for: zona occludens-1, glial-derived neurotrophic factor and claudin.
Human amniotic fluid-derived stem cells may represent a potentially limitless source of ethically neutral, unmodified pluripotential cells for kidney regeneration.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Dialysis and renal transplantation are the only two therapeutic options offered to patients affected by end-stage kidney disease; however, neither treatment can be considered definitive. In fact, dialysis is able to replace only the filtration function of the kidney without substituting its endocrine and metabolic roles, and dramatically impacts on patient's quality of life. On the other hand, kidney transplantation is severely limited by the shortage of transplantable organs, the need for immunosuppressive therapies and a narrow half-life. Regenerative medicine approaches are promising tools aiming to improve this condition. Areas covered: Cell therapies, bioartificial kidney, organ bioengineering, 3D printer and kidney-on-chip represent the most appealing areas of research for the treatment of end-stage kidney failure. The scope of this review is to summarize the state of the art, limits and directions of each branch. Expert opinion: In the future, these emerging technologies could provide definitive, curative and theoretically infinite options for the treatment of end-stage kidney disease. Progress in stem cells-based therapies, decellularization techniques and the more recent scientific know-how for the use of the 3D printer and kidney-on-chip could lead to a perfect cellular-based therapy, the futuristic creation of a bioengineered kidney in the lab or to a valid bioartificial alternative.
    Expert Opinion on Biological Therapy 02/2015; 15(4):1-12. DOI:10.1517/14712598.2015.993376 · 3.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: End stage renal disease (ESRD) is a common disease, which relates to nearly 600 million people in the total population. What is more, it seems to be a crucial problem from the epidemiological point of view. These facts lead to a further necessity of renal replacement therapy development connected with rising expenditures for the health care system. The aim of kidney tissue engineering is to develop and innovate methods of obtaining renal extracellular matrix (ECM) scaffolds derived from kidney decellularization. Recently, progress has been made towards developing a functional kidney graft in vitro on demand. In fact, decellularized tissues constitute ideal natural scaffolds, due to the preservation of native ECM architecture, as well as of cell-ECM binding domains critical in promoting cell attachment, migration, and proliferation. One of the potential sources of the natural scaffolds is the kidney, which cannot be transplanted immediately after excision.
    BioMed Research International 02/2015; 2015:325029. DOI:10.1155/2015/325029 · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Context: Amniotic Fluid Derived Stem Cells (AFSC) has mesenchymal origin and is multipotent. Having played their role in the detection of genetic abnormalities in the unborn children, they are gaining attention in the regenerative medicine because of their pluripotency. Evidence Acquisition: AFSCs possess great proliferating ability and have no ethical and religious issues in their use. AFSCs may also be studied for the stem cells differentiation such as production of multiple lineages of different cells like heart, liver, pancreas, etc. The potential of their use in regenerative medicine as well as their differentiation into multiple cells is possible. Results: AFSCs have the potential to be used in tissue repair and regeneration of bladder and kidney injuries, for the treatment of congenital anomalies like tracheal anomalies and spina bifida therapy etc. However, like every therapeutic potential, AFSCs also have some limitations such as low rate of differentiation of transplanted AFSCs and immune rejection. Conclusions: AFSCs have great therapeutic potential, but extensive research is warranted to overcome the limitations to use AFSC as therapy.
    02/2015; 3(1). DOI:10.5812/rijm.20135

Full-text (2 Sources)

Available from
May 23, 2014